The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

Inc. by Sun Pharmaceutical Industries Limited, which closed on May 30, 2025, after receiving shareholder approval. This acquisition allows Checkpoint to enhance patient access to its FDA-approved ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Today, a brief rundown of news involving Astellas Pharma and Keros Therapeutics ... upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.

"Our strong academic foundation and cutting-edge protein development platform have attracted leading customers across industries including agriculture biotech, pharma biotech, and environmental ...